Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study von Schmid, S., Klingbiel, D., Aeppli, S., Britschgi, C., Gautschi, O., Pless, M., Rothschild, S., Wannesson, L., Janthur, W., Foerbs, D., Demmer, I., Jochum, W., Früh, M.

Volltext

Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study von Schmid, S., Klingbiel, D., Aeppli, S., Britschgi, C., Gautschi, O., Pless, M., Rothschild, S.I., Wannesson De Nicola, L., Janthur, W.-D., Foerbs, D., Demmer, I., Jochum, W., Früh, M.

Volltext

1448PPatterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study von Schmid, S, Klingbiel, D, Aeppli, S, Britschgi, C, Gautschi, O, Pless, M, Rothschild, S I, Wannesson De Nicola, L, Janthur, W-D, Foerbs, D, Demmer, I, Jochum, W, Früh, M

Volltext

Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer von Niederer-Wüst, Séverine M., MD, Jochum, Wolfram, MD, Förbs, Diana, Brändle, Michael, MD, MS, Bilz, Stefan, MD, Clerici, Thomas, MD, Oettli, René, MD, Müller, Joachim, MD, Haile, Sarah R., PhD, Ess, Silvia, MD, Stoeckli, Sandro J., MD, Broglie, Martina A., MD

Volltext